InvestMaryland Provides Biotech Firm, Cellphire, With Development Capital
06/12/2014
“The underlying technology that Cellphire has developed promises to provide a quantum leap forward in how cells are handled and used within healthcare today,” said Cellphire CEO Stephen H. Willard. “Our initial application – platelets – is a perfect example, as untreated platelets last five days outside of a donor’s body. With our patented treatment, we are able to freeze dry platelet derived products for storage measured in years, at room temperature. Reconstitution is as simple as adding sterile water. This investment from MVF enables us to begin pursuing other applications in diagnostics, sports medicine, plastic surgery and dentistry.”
“Supporting entrepreneurs and innovators like those at Cellphire is a central piece of Maryland’s broad support of the startups and small businesses that move our Innovation Economy forward and keep our State competitive in the 21st Century,” said Governor Martin O’Malley. “Maryland is a center of healing and discovery. The technology being developed by Cellphire has the potential to improve care and save lives around the globe.”
Administered by the State’s Maryland Venture Fund, InvestMaryland is a public-private partnership of the State and venture capital firms and is one of Governor Martin O’Malley’s key economic development initiatives.
According to the Maryland Department of Business and Economic Development, last year Cellphire received a contract worth up to $57 million from the Biomedical Advanced Research Defense Authority, a division of U.S. Department of Health & Human Services. The funding will be used to continue development of the company’s freeze-dried platelet product, Thrombosomes, and move it closer to winning Food and Drug Administration approval.
Founded as a bio-defense company in early 2006, Cellphire’s initial focus was on applications within the global blood supply market. The fragility of the blood supply is a concern for agencies and other groups planning a response to potential pandemics, such as avian influenza or other natural or man-made disasters that could interrupt the supply of platelets needed to treat casualties. Cellphire has since expanded its scope, developing technologies and products with diverse applications across blood transfusion, advanced care of chronic and acute wounds and diagnostic reagents used in clinical and research settings.
Project Announcements
Kikkoman Foods Plans Jefferson, Wisconsin, Operations
04/26/2024
BWX Technologies Expands Cambridge, Ontario, Nuclear Production Operations
04/26/2024
Greenheck Group Plans Knoxville, Tennessee, Operations
04/26/2024
Local Bounti Plans Pasco, Washington, Indoor Agricultural Operations
04/26/2024
Innovative Construction Group Plans Siler City, North Carolina, Production Operations
04/26/2024
Crystal Window and Door Systems Plans Mansfield, Texas, Headquarters-Production Operations
04/25/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
Making Hybrid More Human in 2024
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Public-Private Partnerships Incentivize Industrial Development
Q1 2024